Isatuximab Plus RVd Dubbed New Standard Care in Newly Diagnosed Multiple Myeloma

Source: Myeloma – Hematology Advisor

Adding isatuximab to RVd improves the rate of MRD negativity in patients with newly diagnosed, transplant-eligible multiple myeloma, a phase 3 trial suggests.
Read More